It’s time for tech investors to acknowledge the potential of sneaky R&D projects in synthetic biology at Autodesk, Intel, and Microsoft.
It’s time for tech investors to acknowledge the potential of sneaky R&D projects in synthetic biology at Autodesk, Intel, and Microsoft.